Click to see the full list

 

1.         Verdecchia P, Garofoli M, Angeli F, Reboldi G. Response to morning surge, dipping, and sleep-time blood pressure as prognostic markers of cardiovascular risk. Hypertension. 2013;61:e4.

2.         Reboldi G, Angeli F, Verdecchia P. Multivariable analysis in cerebrovascular research: practical notes for the clinician. Cerebrovasc Dis. 2013;35:187-193.

3.         Angeli F, Verdecchia P, Pascucci C, Poltronieri C, Reboldi G. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. Expert Opin Drug Metab Toxicol. 2013;9:379-385.

4.         Angeli F, Reboldi G, Verdecchia P. Hypertension and the J-curve phenomenon: implications for tight blood pressure control. Hypertens Res. 2013;36:109-111.

5.         Angeli F, Reboldi G, Verdecchia P. Modernization and hypertension: is the link changing? Hypertens Res. 2013.

6.         Verdecchia P, Mazzotta G, Angeli F, Reboldi G. Above which blood pressure level does the risk of atrial fibrillation increase? Hypertension. 2012;59:184-185.

7.         Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis. 2012;6:81-91.

8.         Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60:34-42.

9.         Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep. 2012;14:89-96.

10.      Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Blood pressure lowering in diabetic patients. J Hypertens. 2012;30:438-439.

11.      Angeli F, Verdecchia P, Reboldi G. Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. Expert Rev Cardiovasc Ther. 2012;10:1467-1470.

12.      Angeli F, Reboldi G, Verdecchia P. Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. Hypertens Res. 2012;35:17-19.

13.      Angeli F, Reboldi G, Verdecchia P. Microcirculation and left-ventricular hypertrophy. J Hypertens. 2012;30:477-481.

14.      Angeli F, Reboldi G, Verdecchia P. "From apennines to andes:" does body mass index affect the relationship between age and blood pressure? Hypertension. 2012;60:6-7.

15.      Angeli F, Reboldi G, Verdecchia P. Echocardiographic left ventricular hypertrophy: implications for clinicians. J Hypertens. 2012;30:2279-2284.

16.      Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opin Drug Saf. 2012;11:659-670.

17.      Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7:76-85.

18.      Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev. 2012;19:51-54.

19.      Angeli F, Reboldi G, Mazzotta G, Garofoli M, Cerasa MF, Verdecchia P. Statins in acute coronary syndrome: very early initiation and benefits. Ther Adv Cardiovasc Dis. 2012;6:163-174.

20.      Angeli F, Reboldi G, Garofoli M, Ramundo E, Verdecchia P. Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. Acute Card Care. 2012;14:34-39.

21.      Angeli F, Reboldi G, Garofoli M, Ramundo E, Poltronieri C, Mazzotta G, et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep. 2012;14:601-610.

22.      Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol. 2011;4:151-161.

23.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opin Drug Metab Toxicol. 2011;7:115-128.

24.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. 2011;13:176-185.

25.      Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253-1269.

26.      Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment of hypertension. Diabetes Care. 2011;34 Suppl 2:S313-319.

27.      Angeli F, Reboldi G, Verdecchia P. More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension. Hypertens Res. 2011;34:445-447.

28.      Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: still a HOPE for ACE inhibitors? Expert Opin Pharmacother. 2011;12:839-843.

29.      Angeli F, Reboldi G, Verdecchia P. Good news for beta-blockers in perioperative medicine. Expert Opin Drug Saf. 2011;10:491-498.

30.      Angeli F, Reboldi G, Verdecchia P. Lowering blood pressure with beta-blockers in peripheral artery disease: the importance of comorbidity. J Hypertens. 2011;29:1298-1302.

31.      Angeli F, Angeli E, Reboldi G, Verdecchia P. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens. 2011;29:2320-2323.

32.      Angeli F, Angeli E, Ambrosio G, Mazzotta G, Cavallini C, Reboldi G, et al. Neutrophil count and ambulatory pulse pressure as predictors of cardiovascular adverse events in postmenopausal women with hypertension. Am J Hypertens. 2011;24:591-598.

33.      Angeli E, Verdecchia P, Narducci P, Angeli F. Additive value of standard ECG for the risk prediction of hypertensive disorders during pregnancy. Hypertens Res. 2011;34:707-713.

34.      Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. 2010;28:1356-1365.

35.      Verdecchia P, Angeli F, Mazzotta G, Reboldi G. Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol? Am J Hypertens. 2010;23:705.

36.      Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, et al. Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis. 2010;4:193-200.

37.      Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, et al. Treatment strategies for osteoarthritis patients with pain and hypertension. Ther Adv Musculoskelet Dis. 2010;2:229-240.

38.      Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. [Arterial hypertension: an update]. G Ital Cardiol (Rome). 2010;11:74S-77S.

39.      Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertens Res. 2010;33:394-397.

40.      Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol. 2010;8:742-746.

41.      Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Garofoli M, Martire P, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep. 2010;12:302-306.

42.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Blood pressure lowering in the oldest old. J Hypertens. 2010;28:1373-1376.

43.      Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Repaci S, del Pinto M, et al. Beta-blockers and risk of all-cause mortality in non-cardiac surgery. Ther Adv Cardiovasc Dis. 2010;4:109-118.

44.      Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G. ss-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs. 2010;10:247-259.

45.      Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Del Pinto M, Repaci S, et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev. 2010;6:102-110.

46.      Angeli F, Reboldi G, Verdecchia P. Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens. 2010;23:941-948.

47.      Angeli F, Reboldi G, Verdecchia P. "The lower the BP the better" paradigm in the elderly: vanished by VALISH? Hypertension. 2010;56:182-184.

48.      Angeli F, Del Pinto M, Rasetti G, Patriarchi F, Cocchieri M, Mandorla S, et al. [Management of ST-elevation myocardial infarction in the Umbria region: results from the observational prospective Umbria-STEMI registry]. G Ital Cardiol (Rome). 2010;11:393-401.

49.      Angeli F, Angeli E, Cavallini C, Ambrosio G, Mazzotta G, Reboldi G, et al. Electrocardiographic abnormalities of left ventricular repolarization: prognostic implications in hypertensive post-menopausal women. Maturitas. 2010;67:159-165.

50.      Angeli F, Angeli E, Ambrosio G, Mazzotta G, Reboldi G, Verdecchia P. Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. Obstet Gynecol. 2010;115:695-703.

51.      Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-533.

52.      Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag. 2009;5:939-948.

53.      Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension. 2009.

54.      Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home Blood Pressure Measurements Will or Will Not Replace 24-Hour Ambulatory Blood Pressure Measurement. Hypertension. 2009.

55.      Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Repaci S, Pede S, et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens. 2009;27:1697-1704.

56.      Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30:679-688.

57.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009;5:411-427.

58.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther. 2009;7:1349-1361.

59.      Angeli F, Verdecchia P, Del Pinto M, Cavallini C, Reboldi G. Perioperative beta blockade: the debate continues. Lancet. 2009;373:627; author reply 628.

60.      Angeli F, Reboldi G, Gentile G, Verdecchia P. The emerging role of high-density lipoprotein cholesterol in hypertension trials. J Hypertens. 2009;27:458-460.

61.      Verdecchia P, Gentile G, Angeli F, Reboldi G. Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. Pol Arch Med Wewn. 2008;118:513-516.

62.      Verdecchia P, Angeli F, Sardone M, Borgioni C, Garofoli M, Reboldi G. Is the definition of daytime and nighttime blood pressure prognostically relevant? Blood Press Monit. 2008;13:153-155.

63.      Verdecchia P, Angeli F, Reboldi G. Optimizing the definition of dippers and nondippers: is a 70-86% full glass empty? J Hypertens. 2008;26:630-632.

64.      Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag. 2008;4:971-981.

65.      Verdecchia P, Angeli F, Borgioni C, Repaci S, Guerrieri M, Andreani F, et al. Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. J Am Soc Hypertens. 2008;2:88-96.

66.      Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-1289.

67.      Angeli F, Reboldi G, Repaci S, Garofoli M, Casavecchia M, Ambrosio G, et al. [Ambulatory blood pressure monitoring in clinical practice]. G Ital Cardiol (Rome). 2008;9:402-407.

68.      Angeli F, Gentile G, Reboldi G, Verdecchia P. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. Expert Rev Cardiovasc Ther. 2008;6:1171-1174.

69.      Verdecchia P, Reboldi G, Angeli F, Avanzini F, de Simone G, Pede S, et al. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens. 2007;20:997-1004.

70.      Verdecchia P, Cavallini C, Angeli F, Andreani F, Garofoli M, Reboldi GP, et al. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers]. G Ital Cardiol (Rome). 2007;8:491-497.

71.      Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension. 2007;50:459-460.

72.      Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. 2007;20:154-161.

73.      Verdecchia P, Angeli F, Gattobigio R, Borgioni C, Castellani C, Sardone M, et al. The clinical significance of white-coat and masked hypertension. Blood Press Monit. 2007;12:387-389.

74.      Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation. 2007;115:2091-2093.

75.      Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Reboldi G. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension. 2007;49:777-783.

76.      Verdecchia P, Angeli F, Achilli P, Castellani C, Repaci S, Ambrosio G. [Beta-blockers and arterial hypertension. Evidence-based medicine or excessive perseverance?]. G Ital Cardiol (Rome). 2007;8:552-558.

77.      Verdecchia P, Angeli F, Achilli P, Castellani C, Broccatelli A, Gattobigio R, et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol. 2007;22:329-334.

78.      Verdecchia P, Angeli F. Does brachial pulse pressure predict coronary events? Adv Cardiol. 2007;44:150-159.

79.      de Simone G, Schillaci G, Chinali M, Angeli F, Reboldi GP, Verdecchia P. Estimate of white-coat effect and arterial stiffness. J Hypertens. 2007;25:827-831.

80.      Verdecchia P, Angeli F, Taddei S. At the beginning of stiffening: endothelial dysfunction meets "pulsology". Hypertension. 2006;48:541-542.

81.      Verdecchia P, Angeli F, Staessen JA. Compared with whom? Addressing the prognostic value of ambulatory blood pressure categories. Hypertension. 2006;47:820-821.

82.      Verdecchia P, Angeli F, Reboldi G, Gattobigio R. Is the development of diabetes with antihypertensive therapy a problem?--Pro. J Clin Hypertens (Greenwich). 2006;8:120-126.

83.      Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens. 2006;19:493-499.

84.      Verdecchia P, Angeli F, Gattobigio R, Angeli E, Pede S, Pittavini L. Validation of the A&D UA-705 device for self-measurement of blood pressure according to the British Hypertension Society protocol. Blood Press Monit. 2006;11:223-227.

85.      Angeli F, Verdecchia P, Angeli E, Poeta F, Sardone M, Bentivoglio M, et al. Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placement. J Cardiovasc Med (Hagerstown). 2006;7:812-816.

86.      Angeli F, Sardone M, Angeli E, Repaci S, Gattobigio R, Verdecchia P. Validation of the A&D wrist-cuff UB-511 (UB-512) device for self-measurement of blood pressure. Blood Press Monit. 2006;11:349-354.

87.      Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.

88.      Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-392.

89.      Verdecchia P, Angeli F, Reboldi GP, Gattobigio R. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep. 2005;7:174-179.

90.      Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension. 2005;45:412-418.

91.      Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26:2381-2386.

92.      Verdecchia P, Angeli F. Natural history of hypertension subtypes. Circulation. 2005;111:1094-1096.

93.      Verdecchia P, Angeli F. The natural history of white-coat hypertension in the long term. Blood Press Monit. 2005;10:65-66.

94.      Verdecchia P, Angeli F. How can we use the results of ambulatory blood pressure monitoring in clinical practice? Hypertension. 2005;46:25-26.

95.      Verdecchia P, Angeli F. Antihypertensive drugs and coronary artery disease : evidence from controlled trials. High Blood Press Cardiovasc Prev. 2005;12:119-124.

96.      Reboldi G, Gentile G, Angeli F, Verdecchia P. Microalbuminuria and hypertension. Minerva Med. 2005;96:261-275.

97.      Angeli F, Verdecchia P, Gattobigio R, Sardone M, Reboldi G. White-coat hypertension in adults. Blood Press Monit. 2005;10:301-305.

98.      Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Borgioni C, Filippucci L, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press. 2004;13:295-303.

99.      Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.

100.    Verdecchia P, Angeli F, Poeta F, Reboldi GP, Borgioni C, Pittavini L, et al. Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure. Blood Press Monit. 2004;9:225-229.

101.    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. 2004;5:505-510.

102.    Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? J Hum Hypertens. 2004;18 Suppl 2:S23-28.

103.    Verdecchia P, Angeli F, Gattobigio R. Clinical usefulness of ambulatory blood pressure monitoring. J Am Soc Nephrol. 2004;15 Suppl 1:S30-33.

104.    Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther. 2004;26:460-472.

105.    Verdecchia P, Angeli F. Reversal of left ventricular hypertrophy: what have recent trials taught us? Am J Cardiovasc Drugs. 2004;4:369-378.

106.    Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol. 2004;93:240-243.

107.    Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817-822.

108.    Verdecchia P, Sleight P, Avanzini F, de Simone G, Pede S, Perticone F, et al. Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients. Ital Heart J. 2003;4:479-483.

109.    Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-223.

110.    Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-652.

111.    Verdecchia P, Angeli F, Gattobigio R, Porcellati C. Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. Expert Rev Cardiovasc Ther. 2003;1:79-89.

112.    Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895-899.

113.    Verdecchia P, Angeli F. [The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready]. Rev Esp Cardiol. 2003;56:843-847.

114.    Pasqualini L, Marchesi S, Vaudo G, Siepi D, Angeli F, Paris L, et al. Association between endothelial dysfunction and major cardiovascular events in peripheral arterial disease. Vasa. 2003;32:139-143.

115.    Bagliani G, Michelucci A, Angeli F, Meniconi L. Atrial activation analysis by surface P wave and multipolar esophageal recording after cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2003;26:1178-1188.

116.    Angeli F, Verdecchia P, Pellegrino C, Pellegrino RG, Pellegrino G, Prosciutti L, et al. Association between periodontal disease and left ventricle mass in essential hypertension. Hypertension. 2003;41:488-492.

117.    Verdecchia P, Reboldi G, Porcellati C, Schillaci G, Pede S, Bentivoglio M, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol. 2002;39:878-885.